Kornimate/medical-research-clean huggingface dataset:
clinical characteristics and prognosis of acute stroke in pregnancy and puerperium

Conditions: Pregnancy-associated or Puerperium-associated Acute Stroke

Summary: the objectives of this study are: (1) to describe the detailed clinical characteristics and prognosis of aspp patients in order to explore the risk factors of aspp, and to compare the short-term and long-term functional recovery outcomes between them and their controls; (2) to evaluate the risk of recurrent stroke, particularly during subsequent pregnancies, in aspp patients; (3) to assess the short-term and long-term outcomes of their offsprings and their future development status. this study is divided into three parts. the first part is a case-control study to explore the risk factors of aspp and the predictors of the prognosis of aspp patients. the second part is a cohort study to evaluate the impact of aspp on the risk of recurrent stroke. the third part is a cohort study to assess the impact of aspp on the short-term and long-term outcomes of their offsprings by comparing the offsprings of aspp patients with the offsprings of non-aspp participants.


Eligibility criteria:
1. case-control study and cohort study on recurrent stroke risk: inclusion criteria: 1. female patients ≥18 years of age; 2. patients or their legally acceptable representatives or relatives agree to collect personal information for this study and sign an oral or online written informed consent. exclusion criteria: 1. patients or their legally acceptable representatives or relatives refuse follow-up; 2. patients missing critical baseline demographic, clinical or neuroimaging data. 2. cohort study on offspring outcomes: inclusion criteria: 1. female patients ≥18 years of age; 2. patients in pregnancy or within 6 weeks postpartum; 3. patients or their legally acceptable representatives or relatives agree to collect personal information for this study and sign an oral or online written informed consent. exclusion criteria: 1. patients or their legally acceptable representatives or relatives refuse follow-up; 2. patients missing critical baseline demographic, clinical or neuroimaging data; 3. patients whose offsprings have congenital malformation or inborn error of metabolism; 4. patients with complications which may affect cerebral blood flow supply, such as amniotic fluid embolism, in pregnancy; 5. patients whose family members other than the parents and siblings of their offsprings have a history of severe mental illness, such as mental retardation, autism and schizophrenia; 6. patients undergo acute myocardial infarction in pregnancy; 7. patients undergo non-spontaneous stroke events due to other causes, such as cerebral infarction or hemorrhage caused by surgery.

Keywords: acute stroke pregnancy puerperium clinical characteristics prognosis
first trimester prediction of gestational diabetes mellitus by continuous glucose monitoring.

Conditions: Gestational Diabetes Mellitus in Pregnancy

Summary: gestational diabetes mellitus (gdm) is the most common complication of pregnancy, with an incidence rate of 10-15% \[1\]. common risk factors for gdm are increased maternal age and weight and as a consequence of women delaying childbirth and increasing incidence of obesity, there is a corresponding increase in the rate of gdm. gdm is associated with an increased risk of maternal and perinatal short and long-term complications . these include macrosomia, shoulder dystocia, neonatal hypoglycaemia, neonatal hyperbilirubinemia, and perinatal mortality. maternal complications include higher risks of hypertensive disorders, perineal trauma, and caesarean section. additionally, both the mothers with gdm and their infants have an increased risk of developing type 2 diabetes mellitus and cardiovascular disease later in life . screening and diagnosis of gdm is currently based on an oral glucose tolerance (ogtt), which is carried out at 26-28 weeks' gestation. in addition, an ogtt is carried out at 11-13 weeks in women considered to be at increased risk of gdm based on their demographic characteristics and medical history. screening and diagnosis of gdm is traditionally delayed until the late second or early third trimester of pregnancy with the rationale that the diabetogenic effects of pregnancy increase with gestation and therefore delayed testing would maximize the detection rate.


Eligibility criteria:
inclusion criteria: * maternal age ≥ 18 years * planned antenatal care at the same centre (i.e. not planning to move before delivery). * singleton pregnancy. * informed and written consent. exclusion criteria: * age \<18 years; * multiple pregnancy in current pregnancy; * unconscious or very ill; · serious mental illness; * learning difficulties; * not fluent in local language and absence of interpreter; * severe congenital anomaly on ultrasound; * pre-existing diabetes mellitus type 1 or 2; * patients undergoing metformin therapy for infertility. * significant pre-pregnancy comorbidities that increase risk in pregnancy, for example renal failure, severe liver disease, transplantation, cardiac failure, psychiatric conditions requiring in-patient admission (\<1 year); * significant co-morbidity in the current pregnancy, nephropathy (estimated gfr \<60ml/min), other physical or psychological conditions likely to interfere with the conduct of the study and/or interpretation of the trial results; * participating in another intervention study that influences outcomes of this study; * allergy to adhesive materials; * allergy to any of the components of the glucose test:
role of chronic endometritis in postoperative recurrence of severe intrauterine adhesions

Conditions: Intrauterine Adhesions; Chronic Endometritis

Summary: this study is to evaluate the prevalence of chronic endometritis (ce) in women with severe intrauterine adhesions and compare recurrence of adhesion in women with and without ce.

chronic endometritis (ce) is a persistent in endometrium that is characterized by the presence of plasma cells. recently, there has been increasing interest in the role of ce in recurrent pregnancy loss (rpl). one of the most common uterine abnormalities for rpl is intrauterine adhesion (iua).intrauterine adhesion, also known as asherman's syndrome, is the partial or complete occlusion of the uterine cavity as a result of endometrium damage. most intrauterine adhesions patients manifest amenorrhea, reduced menstrual pattern, infertility, and intrauterine growth restriction, which seriously affect their reproductive health.it is well established that the formation of iua likely involves hypoxia, reduced neovascularization, and altered expression of adhesion-associated cytokines, but the exact mechanisms are not well understood. although excessive curettage is considered the primary cause, intrauterine adhesion is known to be associated with diverse non-traumatic factors, such as postabortal sepsis, puerperal sepsis and infections. it is therefore possible to hypothesize that intrauterine adhesion may be related to chronic endometritis. to the best of researchers knowledge,there have been no reports investigating this relationship. the aim of this study was to clarify the hypothesis by evaluating the prevalence of chronic endometritis (ce) in women with severe intrauterine adhesions and compare recurrence of adhesion in women with and without chronic endometritis (ce).

Eligibility criteria:
inclusion criteria: * pre-operative adhesion score was ≥5 * the prior menstrual cycle was regular, and the sex hormone was normal * with informed consent * absence of other uterine abnormality at transvaginal ultrasound * there were no severe systemic diseases, and no contradictions to aspirin, estrogen and surgery. exclusion criteria: * pre-operative adhesion score was \<5 * prior menstrual cycle was irregular and sex hormone was abnormal, or patients had endocrine factors that caused amenorrhea, menstrual reduction and infertility * other uterine abnormality at transvaginal ultrasound * without informed consent * patients had contradictions to estrogen and aspirin such as cancers (breast cancer and endometrial cancer), thrombotic diseases, allergy to antipyretic analgesics, severe liver injury, hypoprothrombinemia, vitamin k deficiency, hemophilia, thrombocytopenia, gastric or duodenal ulcer and asthma * refuse endometrial biopsy * vaginal discharge abnormal, or suspected vaginitis or pelvic inflammatory disease, or using antibiotics.

Keywords: intrauterine adhesions chronic endometritis infections hysteroscopy
effect of antacids on the pharmacokinetics of raltegravir

Conditions: HIV Infections

Summary: the purpose of this study is to test whether there is a drug interaction between raltegravir (a medicine used to treat the human immunodeficiency virus or hiv) and antacids.

this study will determine if an interaction occurs between the hiv medicine raltegravir and an antacid. a prior study found an interaction with another medicine like raltegravir called elvitegravir and an antacid. the elvitegravir levels were reduced by half. the same interaction may occur with raltegravir and an antacid based on the structure of this medicine and how it works. when the levels of hiv medications are reduced, people with hiv can "fail" their treatment. the virus can multiply when the drug levels are too low and the medications can stop working. we need to be sure that antacids will not cause this problem with raltegravir.

Eligibility criteria:
inclusion criteria: * absence of hiv-1 infection as documented by any licensed elisa test kit within 21 days prior to study entry. * age greater than or equal to 18 but less than or equal to 60 years. * ability and willingness to give written informed consent. * within 30% (+/-) of ideal body weight and total body weight of ≥ 50 kg. * hematology, metabolic profile, renal, and hepatic function tests all within normal limits. * creatine kinase (ck) less than 3 times the upper limit of normal exclusion criteria: * pregnancy or breast-feeding. * women and men of reproductive potential who are actively engaging in sexual activity or assisted reproductive technology with the intent of pregnancy. * allergy/sensitivity to raltegravir. * allergy/sensitivity to antacids. * active drug or alcohol abuse or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements. while on study, subjects will be instructed not to consume alcohol for 48 hours prior the screening visit, and for the 24 hours preceding the intensive pharmacokinetic (pk) study visits and for 24 hours following the completion of the study visits. * any medical condition that, in the opinion of the investigator, would interfere with the subject's ability to participate in this protocol. * participation in any investigational drug studies within 30 days prior to study entry. * history of or active cardiovascular, renal, hematologic, hepatic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease(s). this is inclusive of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, any chronic gastrointestinal conditions that might interfere with drug absorption. * use of investigational, prescription, and over-the-counter medications within 14 days of study entry with the following exceptions: aspirin, acetaminophen, ibuprofen, and oral contraceptives

Keywords: hiv antiretroviral drug interaction human immunodeficiency virus
first line metastatic breast cancer treatment (esmeralda)

Conditions: Metastatic Breast Cancer

Summary: the efficacy of eribulin is now well known in metastatic breast cancer. furthermore, a phase iii combine study ( chemo + bev)in metastatic first line shown a gain in pfs with no extra toxicities. it could be interesting to explore the combination of bev + eribulin in first line metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * age \> 18 ans * patient with metastatic mammary adenocarcinoma * hormone receptors er and pr positive or negative for her 2 negative exclusion criteria: * prior chemotherapy for metastatic disease * previous treatment with eribulin or bevacizumab * presence of symptomatic brain metastases or meningeal
comparison of transversalis fascia plane block and erector spinae plane blocks in cesarean section

Conditions: Pain; Postoperative Pain

Summary: cesarean section is one of the most common major surgical procedures performed worldwide,, post-cesarean analgesia should provide adequate pain control while allowing the mother to remain active to meet the needs of the baby. insufficient analgesia after cesarean section may be associated with acute postoperative pain, chronic pain, higher opioid consumption, delayed functional capacity, and postpartum depression. techniques such as neuraxial techniques, oral and intravenous agents, wound infiltration, and behavioral therapy can be used in the treatment of post-cesarean pain pain. in addition, transversus abdominis plane block (tap), quadratus lumborum block (qlb), erector spina block (esp), transversalis fascia plane block (tfp) are used safely under ultrasound guidance. in this study, it was aimed primarily to examine the effects of tfp and esp blocks on pain scores, and secondarily to evaluate analgesic consumption.


Eligibility criteria:
inclusion criteria: * between 18-50 years * cesarean section exclusion criteria: * cesarean section under general anesthesia * emergency cases * those with a body mass index greater than 35 kg/m2 * coagulopathy * local infection
an observational study of methoxy polyethylene glycol-epoetin beta in participants with a kidney transplant

Conditions: Anemia, Kidney Transplantation

Summary: this observational study will investigate efficacy and safety of methoxy polyethyleneglycol-epoetin beta in participants with a kidney transplant. data of each participant will be collected over 15 months of mircera therapy.


Eligibility criteria:
inclusion criteria: * participants with kidney transplant and a chronic kidney disease (ckd), who need erythropoiesis stimulating agent (esa) therapy as part of their medical care and prescribed methoxy polyethyleneglycol-epoetin beta by the doctor. * the transplant should function regularly and without need of continuous dialysis treatment at inclusion and also during the documentation period of this study according to treating physician's prognosis. exclusion criteria: * kidney transplantation dates back less than 3 months. acute decrease of hemoglobin (hb) before enrollment, defined as decrease of greater than or equal to (\>/=) 2 g/dl between two sequential values. * administration of other esa therapies during the observation period.
preserve-zenith® branch endovascular graft-iliac bifurcation clinical study

Conditions: Aortoiliac Aneurysms; Iliac Aneurysms

Summary: the purpose of this extended study is to evaluate the safety and effectiveness of the zenith® branch endovascular graft-iliac bifurcation in combination with the commercially available atrium icast™ covered stent in patients in a treatment of aortoiliac and iliac aneurysms.


Eligibility criteria:
inclusion criteria: * an aortioiliac or iliac aneurysm * an unsuitable distal sealing site for a traditional zenith iliac leg graft within the common lilac artery exclusion criteria: * less than 18 years of age * inability or refusal to give informed consent * disease considerations that would compromise patient safety or study outcomes * pregnant, breast-feeding or planning on becoming pregnant prior to completion of the study * unwilling or unable to comply with the follow-up schedule * simultaneously participating in another investigative device or drug study

Keywords: zenith aortoiliac aneurysm iliac aneurysm branch connections endovascular graft graft-iliac bifurcation aneurysm vascular diseases cardiovascular diseases
evaluation of cogmed working memory training for adult hearing aid users

Conditions: Hearing Loss

Summary: a double-blind randomised active-controlled trial aims to assess whether cogmed (adaptive) working memory training results in improvements in untrained measures of cognition, speech perception and self-reported hearing abilities in older adults (50-74 years) with mild-moderate hearing loss who are existing hearing aid users, compared with an active placebo cogmed (non-adaptive) control. it is hypothesised that improvements on trained cogmed tasks, representing increased working memory capacity, will result in improved performance on cognitive and speech perception tasks that engage working memory. we also measure self-reported hearing ability to assess self-perceived benefit of cogmed training.

one in ten people aged between 55-74 years have a significant hearing impairment in their better hearing ear (as defined by audiometric hearing thresholds). yet, it is becoming increasingly clear that the challenges faced by older listeners cannot be explained by the audiogram. the ability for people with hearing loss to use cognition to support context allows for compensation of degraded auditory input, which in turn offers promise for new cognitive-based rehabilitative interventions. working memory is known to be highly associated with language and recent evidence has shown significant generalisation of on-task learning from cogmed working memory training to improvements in sentence-repetition skills of children with severe to profound hearing loss and use cochlear implants. this evidence offers support for further investigation into the potential benefits of working memory training to improve speech perception abilities in other hearing impaired populations. this study aims to assess whether cogmed (adaptive) working memory training improves the listening abilities of adults with mild to moderate hearing loss as assessed using untrained measurers of cognition, speech perception and self-reported hearing ability, compared with an active control (cogmed, non-adaptive) group. a 6 month follow-up will assess retention of any training-related improvements in outcomes for the adaptive training group.

Eligibility criteria:
inclusion criteria: * existing (3+ months) hearing aid(s) user * mild to moderate (pta0.25-4k hz 21-69 db hl) sensorineural hearing loss (snhl) in the better hearing ear (snhl defined as air-bone gap across 0.5k, 1k \& 2k hz \< 15 db) * internet access at home exclusion criteria: * participation in a previous training intervention study * first language other than english (all speech outcome measure are presented in english) * unable to use either a desktop or laptop computer (cogmed rm working memory training is delivered via the internet using a desktop or laptop computer) * cognitive impairment as defined as a score of less than 26/30 (fail) on the montreal cognitive assessment (moca)

Keywords: hearing loss hearing aid speech intelligibility speech perception cognitive training working memory working memory training
sirius in gynaecological laparoscopic surgery

Conditions: Ovarian Cancer; Cervical Cancer; Gynecologic Cancer

Summary: precision robotics' sirius robotic flexible endoscopic system is a new fully integrated compact 3d laparoscopic camera system with a disposable single-use flexible tip that can change its viewing direction. a prospective study to evaluate the clinical performance and safety of the sirius endoscope system in laparoscopic gynecological surgery. the study is a single-arm prospective study to evaluate the performance and safety of the sirius endoscope system.

minimally invasive surgery (mis) is well established in gynecological surgery. compared to laparotomy, mis is associated with reduced morbidity and quicker recovery. with advancement in laparoscopic technology and techniques, mis in gynecology has progressed from multi-port to single incision laparoscopic surgery (sils) and vaginal natural orifice transluminal endoscopic surgery (vnotes), thus further reducing morbidity and enhancing recovery. one of the challenges of mis is the restriction of the range of surgical movement. to overcome these technical challenges, articulated instruments are increasingly being used. the sirius endoscope system is a new, fully integrated compact 3d laparoscopic camera system with a disposable single-use flexible tip that can change its viewing direction. the articulated tip has three degrees of freedom, enabling c and s-shaped bending, and providing a wider field of view compared to conventional laparoscopes. this wider field of view is of advantage for sils and vnotes. presently available commercial systems do not have the same field of view or degrees of freedom. a first in-human, proof of concept, and early development study of the sirius endoscope system was done at ghk in 2021 (hku-ghk irb 2021-01, clinicaltrials.gov nct05048407). the successful completion of 11 of 13 (85%) planned procedures in this sequentially reported, prospective case series, shows that the sirius endoscope system can be used with indications of safety, and efficacy for intermediate and major mis laparoscopic procedures in gynecology. the findings have been submitted for consideration for publication. based on the outcome of this study, further improvements to the sirius endoscope system have been made to enhance safety, reliability, and usability. this proposed prospective study is a confirmatory study to evaluate the performance and safety of the sirius endoscope system in preparation for regulatory approval.

Eligibility criteria:
inclusion criteria: eligible women, 18 or older, who are planned for laparoscopic gynaecological surgery and willing to provide informed consent prior to surgery exclusion criteria: 1. patient is pregnant, or planning on becoming pregnant 2. obese patients (bmi \>35) 3. patient with known contraindication(s) to laparoscopic gynecological surgery 4. patient with operations planned for longer than 4 hours 5. subjects are considered ineligible for the study as judged by the investigator.
novocart 3d treatment following microfracture failure

Conditions: Articular Cartilage Defect

Summary: this study is prospective single arm extension study of protocol aag-g-h-1220. it is open only to participants of aag-g-h-1220 randomized to the microfracture treatment group.

this study is an extension of protocol aag-g-h-1220 wherein patients were randomized to either novocart 3d or microfracture treatment groups. this prospective single arm extension study is only open to participants of aag-g-h-1220 who were randomized to microfracture treatment and who failed microfracture treatment.

Eligibility criteria:
inclusion criteria: * participated in study aag-g-h-1220 * identified as a microfracture failure patient * voluntary consent to participate in the study exclusion criteria: * other cartilage repair procedures performed on target knee * other conditions that would interfere with healing or evaluating outcomes * lesions requiring implants larger than 9cm2 * non-compliance with requirements in study aag-g-h-1220

Keywords: cartilage repair cartilage regeneration cartilage reconstruction cartilage restoration autologous chondrocyte implantation matrix associated chondrocyte implantation